论文部分内容阅读
从原料制备,到药品销售,再到临床应用,我国生物医药产业坐拥了巨大市场,并且近年来呈现爆发式增长。但在制药技术更新换代迅速和跨国企业进军中国的双重压力之下,国内生物制药行业的生产能力能否与如此巨大的市场匹配呢?事实上,在疫苗、输液产品、动物用药等工艺要求较低的领域,产能过剩现象已经存在。在生物医药这一领域,在癌症研究、免疫治疗、干细胞等方面,近年来新药开发面临着前所未有
From raw material preparation, to drug sales, and then to clinical application, China’s biomedicine industry has enjoyed a huge market and has shown explosive growth in recent years. However, with the rapidly changing pharmaceutical technology and the dual pressures of multinationals entering China, can the domestic biopharmaceutical industry’s production capacity match such a huge market? In fact, in the fields of vaccines, infusion products, and animal medicines, Low areas, overcapacity already exists. In the field of biomedicine, in the fields of cancer research, immunotherapy, stem cells and the like, the development of new drugs is facing an unprecedented trend in recent years